About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Diabetes and Metabolism Research Group is search is lead by Dr. Rafael Simó (Hirsch index:54), Head of the Endocrinology Department, Professor of Medicine & Endocrinology at UAB and current President of the European Association for the Study of Diabetes-Eye Complications. The group consists of 7 senior clinical investigators, 4 basic post-doctoral researchers, 4 pre-doc researchers, 3 laboratory technicians and one coordinator of clinical assays.
The group belongs to “CIBER” of Diabetes and Associated Metabolic Diseases (CIBERDEM. ISCIII) and has been recognized as consolidated group by the Generalitat de Catalunya (AQU/AGAUR).
Since 2014 this group has been qualified as outstanding in the evaluations performed by the ANEP, CIBERDEM and the external Scientific Advisory Board of VHIR.
The main lines of research are:
IP: Andreea Ciudin Mihai Collaborators: Manuel Escobar Amores, Nuria Roson Gradaille, Fiorella Ximena Palmas Candia, Aitor Rodriguez Martinez, Marta Comas Martínez, Enzamaría Fidilio Meli Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 431460 Reference: CPP2023-010524 Duration: 01/11/2024 - 30/10/2027
IP: Inmaculada Fuentes Camps Collaborators: Antonio Moreno Galdó, Rafael Simó Canonge, Ariadna Martín Balcells, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi, Joan Genescà Ferrer, Gemma Vona Giralt, Paula Isabel Roldan Caballero Funding agency: Instituto de Salud Carlos III Funding: 274920 Reference: PT23/00062 Duration: 01/01/2024 - 31/12/2026
IP: José Raul Herance Camacho Collaborators: Beatriz Minguez Rosique, Clara Ramírez Serra, Cristina Gamez Cenzano, Juan Manuel Pericàs Pulido, Nuria Roson Gradaille, Andreea Ciudin Mihai, Alberto Roque Pérez, ARTEMIs: AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients, Maria Nazarena Pizzi, Ramón Vilallonga Puy, Enrique Franky Vargas, Carolina Aparicio Gomez Funding agency: EUROPEAN COMMISSION Funding: 724000 Reference: ARTEMIS_HE-HLTH2023 Duration: 01/01/2024 - 31/12/2027
IP: Rafael Simó Canonge Collaborators: Maria Llorian Salvador, Miriam Izquierdo Sans Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 152348.46 Reference: 2022 BP 00067 Duration: 01/04/2024 - 31/03/2027
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.
The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.
